Study Evaluating Safety and Effectiveness of Etentamig and ABBV-2001 Treatments in Adults with Multiple Myeloma

What this Trial Is About

Multiple myeloma MM is a cancer affecting the plasma cells in bone marrow, often causing bone pain, fractures, infections, and kidney problems. This research is exploring the safety, effectiveness, and how the body processes two investigational drugs, Etentamig and ABBV-2001, in adults with MM. The study involves six substudies, each with dose escalation and expansion phases, to examine different drug combinations and dosages. Participants in substudies 1 to 4 receive increasing doses of Etentamig alone or combined with treatments such as daratumumab with lenalidomide DR, carfilzomib with dexamethasone Kd, or lenalidomide R. They may also receive comparator treatments like DRd, R, or DKd during dose expansion. Substudies 5 and 6 involve ABBV-2001 with oral iberdomide or mezigdomide, given as injections and oral medications, respectively. The study duration is approximately 130 months. During the trial, participants attend regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers measure adverse events, dose-limiting toxicity, response rates, progression-free survival, duration of response, and minimal residual disease negativity across substudies. The study aims to carefully evaluate these investigational treatments over a long-term period to understand their impact on MM.

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations